HAART-prolonged life of HIV-infected patients should not be shortened by hepatitis C.

As highly active antiretroviral treatment (HAART) prolongs the life of HIV-infected individuals and reduces mortality associated with opportunistic infections, liver diseases have become a major challenge in the management of these patients. Up to 45% of deaths of persons with HIV are related to end-stage liver disease, some of which might have been avoided with a less hesitant approach to hepatitis C treatment in the setting of HIV/ hepatitis C (HCV) coinfection.